Hyaluronan as a therapeutic target in human diseases

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 186-203

  Liang, Jiurong ^a   Jiang, Dianhua ^a   Noble, Paul W ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Extracellular matrix; Hyaluronan

Indexed keywords

BINS; CELL MEMBRANES; GENE EXPRESSION; GENE EXPRESSION REGULATION; HYALURONIC ACID; PROTEINS; REPAIR; TISSUE;

BINDING PARTNERS; BINDING PROTEINS; EXTRACELLULAR MATRICES; HYALURONAN; INFLAMMATORY RESPONSE; NEW APPROACHES; PATHOLOGICAL PROCESS; THERAPEUTIC TARGETS;

TISSUE REGENERATION;

BINDING PROTEIN; CISPLATIN; DOXORUBICIN; DRUG CARRIER; ENZYME INHIBITOR; FLUOROURACIL; GEMCITABINE; GLYCYRRHIZIC ACID; HYALURONAN BINDING PROTEIN; HYALURONAN SYNTHASE; HYALURONIC ACID; HYALURONIDASE; HYALURONIDASE INHIBITOR; HYMECROMONE; INSULIN; IRINOTECAN; PACLITAXEL; POLYMER; SYNTHETASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; ASTHMA; BILE DUCT DISEASE; BREAST CANCER; CARCINOMATOUS PERITONITIS; CELL INVASION; CELL MIGRATION; CELLS BY BODY ANATOMY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLAGEN-INDUCED ARTHRITIS; COUGHING; CYSTALGIA; CYSTIC FIBROSIS; DEVELOPMENT; DIABETES MELLITUS; DIFFERENTIATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; EMPHYSEMA; ENTERITIS; EXTRACELLULAR MATRIX; GENE EXPRESSION; GRAFT REJECTION; GROWTH; HEART DISEASE; HEPATITIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTERSTITIAL CYSTITIS; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER FIBROSIS; LUNG FIBROSIS; LUNG INJURY; METASTASIS; METASTATIC COLORECTAL CANCER; NEOPLASM; NONHUMAN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PNEUMONIA; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; REPERFUSION INJURY; REVIEW; SENESCENCE; STEM CELL; THROAT IRRITATION; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; CHEMISTRY; DISEASES; METABOLISM;

ANIMALS; DISEASE; HUMANS; HYALURONIC ACID;

EID: 84957803146     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.017     Document Type: Review

References (335)

1. Lee J.Y., Spicer A.P. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr. Opin. Cell Biol. 2000, 12:581-586.
2. Toole B.P. Hyaluronan is not just a goo!. J. Clin. Invest. 2000, 106:335-336.
3. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4:528-539.
4. Slevin M., Krupinski J., Gaffney J., Matou S., West D., Delisser H., Savani R.C., Kumar S. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol. 2007, 26:58-68.
5. Jiang D., Liang J., Noble P.W. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011, 91:221-264.
6. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., Prestwich G.D., Mascarenhas M.M., Garg H.G., Quinn D.A., Homer R.J., Goldstein D.R., Bucala R., Lee P.J., Medzhitov R., Noble P.W. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 2005, 11:1173-1179.
7. Jameson J.M., Cauvi G., Sharp L.L., Witherden D.A., Havran W.L. γδ T cell-induced hyaluronan production by epithelial cells regulates inflammation. J. Exp. Med. 2005, 201:1269-1279.
8. Beck-Schimmer B., Oertli B., Pasch T., Wuthrich R.P. Hyaluronan induces monocyte chemoattractant protein-1 expression in renal tubular epithelial cells. J. Am. Soc. Nephrol. 1998, 9:2283-2290.
9. Zoltan-Jones A., Huang L., Ghatak S., Toole B.P. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J. Biol. Chem. 2003, 278:45801-45810.
10. Jiang D., Liang J., Li Y., Noble P.W. The role of Toll-like receptors in non-infectious lung injury. Cell Res. 2006, 16:693-701.
11. Itano N., Atsumi F., Sawai T., Yamada Y., Miyaishi O., Senga T., Hamaguchi M., Kimata K. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3609-3614.
12. Bai K.J., Spicer A.P., Mascarenhas M.M., Yu L., Ochoa C.D., Garg H.G., Quinn D.A. The role of hyaluronan synthase 3 in ventilator-induced lung injury. Am. J. Respir. Crit. Care Med. 2005, 172:92-98.
13. Soltes L., Mendichi R., Kogan G., Schiller J., Stankovska M., Arnhold J. Degradative action of reactive oxygen species on hyaluronan. Biomacromolecules 2006, 7:659-668.
14. Stern R., Kogan G., Jedrzejas M.J., Soltes L. The many ways to cleave hyaluronan. Biotechnol. Adv. 2007, 25:537-557.
15. Heldin P., Basu K., Kozlova I., Porsch H. HAS2 and CD44 in breast tumorigenesis. Adv. Cancer Res. 2014, 123:211-229.
16. Schwertfeger K.L., Cowman M.K., Telmer P.G., Turley E.A., McCarthy J.B. Hyaluronan, inflammation, and breast cancer progression. Front. Immunol. 2015, 6:236.
17. Lokeshwar V.B., Mirza S., Jordan A. Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv. Cancer Res. 2014, 123:35-65.
18. Seton-Rogers S. Metastasis: multitasking hyaluronic acid. Nat. Rev. Cancer 2012, 12:228.
19. Knudson C.B., Knudson W. Hyaluronan and CD44: modulators of chondrocyte metabolism. Clin. Orthop. Relat. Res. 2004, S152-162.
20. Turino G.M., Cantor J.O. Hyaluronan in respiratory injury and repair. Am. J. Respir. Crit. Care Med. 2003, 167:1169-1175.
21. Noble P.W. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol. 2002, 21:25-29.
22. Jiang D., Liang J., Noble P.W. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 2007, 23:435-461.
23. Aya K.L., Stern R. Hyaluronan in wound healing: rediscovering a major player. Wound Repair Regen. 2014, 22:579-593.
24. Moretto P., Karousou E., Viola M., Caon I., D'Angelo M.L., De Luca G., Passi A., Vigetti D. Regulation of hyaluronan synthesis in vascular diseases and diabetes. J. Diabetes Res. 2015, 2015:167283.
25. McDonald B., Kubes P. Interactions between CD44 and hyaluronan in leukocyte trafficking. Front. Immunol. 2015, 6:68.
26. Termeer C., Sleeman J.P., Simon J.C. Hyaluronan-magic glue for the regulation of the immune response?. Trends Immunol. 2003, 24:112-114.
27. Jackson D.G. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol. Rev. 2009, 230:216-231.
28. McDonald J.A., Camenisch T.D. Hyaluronan: genetic insights into the complex biology of a simple polysaccharide. Glycoconj. J. 2002, 19:331-339.
29. Itano N., Sawai T., Yoshida M., Lenas P., Yamada Y., Imagawa M., Shinomura T., Hamaguchi M., Yoshida Y., Ohnuki Y., Miyauchi S., Spicer A.P., McDonald J.A., Kimata K. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J. Biol. Chem. 1999, 274:25085-25092.
30. Spicer A.P., Tien J.Y. Hyaluronan and morphogenesis. Birth Defects Res. C Embryo Today 2004, 72:89-108.
31. Kobayashi N., Miyoshi S., Mikami T., Koyama H., Kitazawa M., Takeoka M., Sano K., Amano J., Isogai Z., Niida S., Oguri K., Okayama M., McDonald J.A., Kimata K., Taniguchi S., Itano N. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res. 2010, 70:7073-7083.
32. Mack J.A., Feldman R.J., Itano N., Kimata K., Lauer M., Hascall V.C., Maytin E.V. Enhanced inflammation and accelerated wound closure following tetraphorbol ester application or full-thickness wounding in mice lacking hyaluronan synthases Has1 and Has3. J. Invest. Dermatol. 2012, 132:198-207.
33. Camenisch T.D., Spicer A.P., Brehm-Gibson T., Biesterfeldt J., Augustine M.L., Calabro A., Kubalak S., Klewer S.E., McDonald J.A. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Invest. 2000, 106:349-360.
34. Wang Y., Lauer M.E., Anand S., Mack J.A., Maytin E.V. Hyaluronan synthase 2 protects skin fibroblasts against apoptosis induced by environmental stress. J. Biol. Chem. 2014, 289:32253-32265.
35. Arranz A.M., Perkins K.L., Irie F., Lewis D.P., Hrabe J., Xiao F., Itano N., Kimata K., Hrabetova S., Yamaguchi Y. Hyaluronan deficiency due to Has3 knock-out causes altered neuronal activity and seizures via reduction in brain extracellular space. J. Neurosci. 2014, 34:6164-6176.
36. Stern R., Asari A.A., Sugahara K.N. Hyaluronan fragments: an information-rich system. Eur. J. Cell Biol. 2006, 85:699-715.
37. Martin D.C., Atmuri V., Hemming R.J., Farley J., Mort J.S., Byers S., Hombach-Klonisch S., Csoka A.B., Stern R., Triggs-Raine B.L. A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis. Hum. Mol. Genet. 2008, 17:1904-1915.
38. Muto J., Morioka Y., Yamasaki K., Kim M., Garcia A., Carlin A.F., Varki A., Gallo R.L. Hyaluronan digestion controls DC migration from the skin. J. Clin. Invest. 2014, 124:1309-1319.
39. Jadin L., Wu X., Ding H., Frost G.I., Onclinx C., Triggs-Raine B., Flamion B. Skeletal and hematological anomalies in HYAL2-deficient mice: a second type of mucopolysaccharidosis IX?. FASEB J. 2008, 22:4316-4326.
40. Chowdhury B., Hemming R., Hombach-Klonisch S., Flamion B., Triggs-Raine B. Murine hyaluronidase 2 deficiency results in extracellular hyaluronan accumulation and severe cardiopulmonary dysfunction. J. Biol. Chem. 2013, 288:520-528.
41. de la Motte C., Nigro J., Vasanji A., Rho H., Kessler S., Bandyopadhyay S., Danese S., Fiocchi C., Stern R. Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am. J. Pathol. 2009, 174:2254-2264.
42. Atmuri V., Martin D.C., Hemming R., Gutsol A., Byers S., Sahebjam S., Thliveris J.A., Mort J.S., Carmona E., Anderson J.E., Dakshinamurti S., Triggs-Raine B. Hyaluronidase 3 (HYAL3) knockout mice do not display evidence of hyaluronan accumulation. Matrix Biol. 2008, 27:653-660.
43. Preston M., Gong X., Su W., Matsumoto S.G., Banine F., Winkler C., Foster S., Xing R., Struve J., Dean J., Baggenstoss B., Weigel P.H., Montine T.J., Back S.A., Sherman L.S. Digestion products of the PH20 hyaluronidase inhibit remyelination. Ann. Neurol. 2013, 73:266-280.
44. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 61:1303-1313.
45. Sherman L., Sleeman J., Herrlich P., Ponta H. Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. Curr. Opin. Cell Biol. 1994, 6:726-733.
46. Lesley J., Hyman R., Kincade P.W. CD44 and its interaction with extracellular matrix. Adv. Immunol. 1993, 54:271-335.
47. Schmits R., Filmus J., Gerwin N., Senaldi G., Kiefer F., Kundig T., Wakeham A., Shahinian A., Catzavelos C., Rak J., Furlonger C., Zakarian A., Simard J.J., Ohashi P.S., Paige C.J., Gutierrez-Ramos J.C., Mak T.W. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 1997, 90:2217-2233.
48. Teder P., Vandivier R.W., Jiang D., Liang J., Cohn L., Pure E., Henson P.M., Noble P.W. Resolution of lung inflammation by CD44. Science 2002, 296:155-158.
49. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65:13-24.
50. Arch R., Wirth K., Hofmann M., Ponta H., Matzku S., Herrlich P., Zoller M. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992, 257:682-685.
51. Borjesson P.K., Postema E.J., Roos J.C., Colnot D.R., Marres H.A., van Schie M.H., Stehle G., de Bree R., Snow G.B., Oyen W.J., van Dongen G.A. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 2003, 9:3961S-3972S.
52. Hardwick C., Hoare K., Owens R., Hohn H.P., Hook M., Moore D., Cripps V., Austen L., Nance D.M., Turley E.A. Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility. J. Cell Biol. 1992, 117:1343-1350.
53. Savani R.C., Cao G., Pooler P.M., Zaman A., Zhou Z., DeLisser H.M. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J. Biol. Chem. 2001, 276:36770-36778.
54. Hall C.L., Yang B., Yang X., Zhang S., Turley M., Samuel S., Lange L.A., Wang C., Curpen G.D., Savani R.C., Greenberg A.H., Turley E.A. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995, 82:19-26.
55. Zaman A., Cui Z., Foley J.P., Zhao H., Grimm P.C., Delisser H.M., Savani R.C. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am. J. Respir. Cell Mol. Biol. 2005, 33:447-454.
56. Tolg C., Poon R., Fodde R., Turley E.A., Alman B.A. Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene 2003, 22:6873-6882.
57. Tolg C., Hamilton S.R., Nakrieko K.A., Kooshesh F., Walton P., McCarthy J.B., Bissell M.J., Turley E.A. Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J. Cell Biol. 2006, 175:1017-1028.
58. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell. Mol. Life Sci. 2000, 57:276-289.
59. Jaworski D.M., Kelly G.M., Hockfield S. Intracranial injury acutely induces the expression of the secreted isoform of the CNS-specific hyaluronan-binding protein BEHAB/brevican. Exp. Neurol. 1999, 157:327-337.
60. Jaworski D.M., Kelly G.M., Piepmeier J.M., Hockfield S. BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res. 1996, 56:2293-2298.
61. Yamada H., Fredette B., Shitara K., Hagihara K., Miura R., Ranscht B., Stallcup W.B., Yamaguchi Y. The brain chondroitin sulfate proteoglycan brevican associates with astrocytes ensheathing cerebellar glomeruli and inhibits neurite outgrowth from granule neurons. J. Neurosci. 1997, 17:7784-7795.
62. Deepa S.S., Carulli D., Galtrey C., Rhodes K., Fukuda J., Mikami T., Sugahara K., Fawcett J.W. Composition of perineuronal net extracellular matrix in rat brain: a different disaccharide composition for the net-associated proteoglycans. J. Biol. Chem. 2006, 281:17789-17800.
63. LeBaron R.G., Zimmermann D.R., Ruoslahti E. Hyaluronate binding properties of versican. J. Biol. Chem. 1992, 267:10003-10010.
64. Zimmermann D.R., Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J. 1989, 8:2975-2981.
65. Deb T.B., Datta K. Molecular cloning of human fibroblast hyaluronic acid-binding protein confirms its identity with P-32, a protein co-purified with splicing factor SF2. Hyaluronic acid-binding protein as P-32 protein, co-purified with splicing factor SF2. J. Biol. Chem. 1996, 271:2206-2212.
66. Yagi M., Uchiumi T., Takazaki S., Okuno B., Nomura M., Yoshida S., Kanki T., Kang D. p32/gC1qR is indispensable for fetal development and mitochondrial translation: importance of its RNA-binding ability. Nucleic Acids Res. 2012, 40:9717-9737.
67. Zhou B., Oka J.A., Singh A., Weigel P.H. Purification and subunit characterization of the rat liver endocytic hyaluronan receptor. J. Biol. Chem. 1999, 274:33831-33834.
68. Harris E.N., Kyosseva S.V., Weigel J.A., Weigel P.H. Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J. Biol. Chem. 2007, 282:2785-2797.
69. Harris E.N., Weigel J.A., Weigel P.H. The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin. J. Biol. Chem. 2008, 283:17341-17350.
70. Hirose Y., Saijou E., Sugano Y., Takeshita F., Nishimura S., Nonaka H., Chen Y.R., Sekine K., Kido T., Nakamura T., Kato S., Kanke T., Nakamura K., Nagai R., Ochiya T., Miyajima A. Inhibition of Stabilin-2 elevates circulating hyaluronic acid levels and prevents tumor metastasis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:4263-4268.
71. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., Jones M., Jackson D.G. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 1999, 144:789-801.
72. Prevo R., Banerji S., Ferguson D.J., Clasper S., Jackson D.G. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J. Biol. Chem. 2001, 276:19420-19430.
73. Jang J.Y., Koh Y.J., Lee S.H., Lee J., Kim K.H., Kim D., Koh G.Y., Yoo O.J. Conditional ablation of LYVE-1+ cells unveils defensive roles of lymphatic vessels in intestine and lymph nodes. Blood 2013, 122:2151-2161.
74. Huang L., Yoneda M., Kimata K. A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. J. Biol. Chem. 1993, 268:26725-26730.
75. Lee T.H., Wisniewski H.G., Vilcek J. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J. Cell Biol. 1992, 116:545-557.
76. Milner C.M., Day A.J. TSG-6: a multifunctional protein associated with inflammation. J. Cell Sci. 2003, 116:1863-1873.
77. Lauer M.E., Cheng G., Swaidani S., Aronica M.A., Weigel P.H., Hascall V.C. Tumor necrosis factor-stimulated gene-6 (TSG-6) amplifies hyaluronan synthesis by airway smooth muscle cells. J. Biol. Chem. 2013, 288:423-431.
78. Szanto S., Bardos T., Gal I., Glant T.T., Mikecz K. Enhanced neutrophil extravasation and rapid progression of proteoglycan-induced arthritis in TSG-6-knockout mice. Arthritis Rheum. 2004, 50:3012-3022.
79. Yoshida H., Nagaoka A., Kusaka-Kikushima A., Tobiishi M., Kawabata K., Sayo T., Sakai S., Sugiyama Y., Enomoto H., Okada Y., Inoue S. KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5612-5617.
80. Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P., Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J. Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. J. Natl. Cancer Inst. 2013, 105:1402-1416.
81. Shostak K., Zhang X., Hubert P., Goktuna S.I., Jiang Z., Klevernic I., Hildebrand J., Roncarati P., Hennuy B., Ladang A., Somja J., Gothot A., Close P., Delvenne P., Chariot A. NF-kappaB-induced KIAA1199 promotes survival through EGFR signalling. Nat. Commun. 2014, 5:5232.
82. West D.C., Hampson I.N., Arnold F., Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985, 228:1324-1326.
83. Horton M.R., McKee C.M., Bao C., Liao F., Farber J.M., Hodge-DuFour J., Pure E., Oliver B.L., Wright T.M., Noble P.W. Hyaluronan fragments synergize with interferon-gamma to induce the C-X-C chemokines mig and interferon-inducible protein-10 in mouse macrophages. J. Biol. Chem. 1998, 273:35088-35094.
84. McKee C.M., Lowenstein C.J., Horton M.R., Wu J., Bao C., Chin B.Y., Choi A.M., Noble P.W. Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappaB-dependent mechanism. J. Biol. Chem. 1997, 272:8013-8018.
85. Noble P.W., McKee C.M., Cowman M., Shin H.S. Hyaluronan fragments activate an NF-kappa B/I-kappa B alpha autoregulatory loop in murine macrophages. J. Exp. Med. 1996, 183:2373-2378.
86. McKee C.M., Penno M.B., Cowman M., Burdick M.D., Strieter R.M., Bao C., Noble P.W. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J. Clin. Invest. 1996, 98:2403-2413.
87. Termeer C.C., Hennies J., Voith U., Ahrens T., Weiss J.M., Prehm P., Simon J.C. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J. Immunol. 2000, 165:1863-1870.
88. Hynes W.L., Walton S.L. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol. Lett. 2000, 183:201-207.
89. Agren U.M., Tammi R.H., Tammi M.I. Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture. Free Radic. Biol. Med. 1997, 23:996-1001.
90. Li M., Rosenfeld L., Vilar R.E., Cowman M.K. Degradation of hyaluronan by peroxynitrite. Arch. Biochem. Biophys. 1997, 341:245-250.
91. Babasola O., Rees-Milton K.J., Bebe S., Wang J., Anastassiades T.P. Chemically modified N-acylated hyaluronan fragments modulate proinflammatory cytokine production by stimulated human macrophages. J. Biol. Chem. 2014, 289:24779-24791.
92. Benitez A., Yates T.J., Lopez L.E., Cerwinka W.H., Bakkar A., Lokeshwar V.B. Targeting hyaluronidase for cancer therapy: antitumor activity of sulfated hyaluronic acid in prostate cancer cells. Cancer Res. 2011, 71:4085-4095.
93. Bourguignon L.Y., Gilad E., Brightman A., Diedrich F., Singleton P. Hyaluronan-CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase C epsilon-Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J. Biol. Chem. 2006, 281:14026-14040.
94. Termeer C., Benedix F., Sleeman J., Fieber C., Voith U., Ahrens T., Miyake K., Freudenberg M., Galanos C., Simon J.C. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 2002, 195:99-111.
95. Tesar B.M., Jiang D., Liang J., Palmer S.M., Noble P.W., Goldstein D.R. The role of hyaluronan degradation products as innate alloimmune agonists. Am. J. Transplant. 2006, 6:2622-2635.
96. Liang J., Jiang D., Griffith J., Yu S., Fan J., Zhao X., Bucala R., Noble P.W. CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. J. Immunol. 2007, 178:2469-2475.
97. Muto J., Yamasaki K., Taylor K.R., Gallo R.L. Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS. Mol. Immunol. 2009, 47:449-456.
98. Orian-Rousseau V. CD44 acts as a signaling platform controlling tumor progression and metastasis. Front. Immunol. 2015, 6:154.
99. Khaldoyanidi S., Moll J., Karakhanova S., Herrlich P., Ponta H. Hyaluronate-enhanced hematopoiesis: two different receptors trigger the release of interleukin-1beta and interleukin-6 from bone marrow macrophages. Blood 1999, 94:940-949.
100. Nilsson S.K., Haylock D.N., Johnston H.M., Occhiodoro T., Brown T.J., Simmons P.J. Hyaluronan is synthesized by primitive hemopoietic cells, participates in their lodgment at the endosteum following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro. Blood 2003, 101:856-862.
101. Avigdor A., Goichberg P., Shivtiel S., Dar A., Peled A., Samira S., Kollet O., Hershkoviz R., Alon R., Hardan I., Ben-Hur H., Naor D., Nagler A., Lapidot T. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 2004, 103:2981-2989.
102. Zohar R., Sodek J., McCulloch C.A. Characterization of stromal progenitor cells enriched by flow cytometry. Blood 1997, 90:3471-3481.
103. Calabro A., Oken M.M., Hascall V.C., Masellis A.M. Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. Blood 2002, 100:2578-2585.
104. Zhu H., Mitsuhashi N., Klein A., Barsky L.W., Weinberg K., Barr M.L., Demetriou A., Wu G.D. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. Stem Cells 2006, 24:928-935.
105. Orkin R.W., Toole B.P. Hyaluronidase activity and hyaluronate content of the developing chick embryo heart. Dev. Biol. 1978, 66:308-320.
106. Belsky E., Toole B.P. Hyaluronate and hyaluronidase in the developing chick embryo kidney. Cell Differ. 1983, 12:61-66.
107. Camenisch T.D., Schroeder J.A., Bradley J., Klewer S.E., McDonald J.A. Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat. Med. 2002, 8:850-855.
108. Mjaatvedt C.H., Yamamura H., Capehart A.A., Turner D., Markwald R.R. The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Dev. Biol. 1998, 202:56-66.
109. Shirai M., Imanaka-Yoshida K., Schneider M.D., Schwartz R.J., Morisaki T. T-box 2, a mediator of Bmp-Smad signaling, induced hyaluronan synthase 2 and Tgfβ2 expression and endocardial cushion formation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18604-18609.
110. Li Y., Toole B.P., Dealy C.N., Kosher R.A. Hyaluronan in limb morphogenesis. Dev. Biol. 2007, 305:411-420.
111. Matsumoto K., Li Y., Jakuba C., Sugiyama Y., Sayo T., Okuno M., Dealy C.N., Toole B.P., Takeda J., Yamaguchi Y., Kosher R.A. Conditional inactivation of Has2 reveals a crucial role for hyaluronan in skeletal growth, patterning, chondrocyte maturation and joint formation in the developing limb. Development 2009, 136:2825-2835.
112. Liu J., Li Q., Kuehn M.R., Litingtung Y., Vokes S.A., Chiang C. Sonic hedgehog signaling directly targets Hyaluronic Acid Synthase 2, an essential regulator of phalangeal joint patterning. Dev. Biol. 2013, 375:160-171.
113. Hunt L.C., Gorman C., Kintakas C., McCulloch D.R., Mackie E.J., White J.D. Hyaluronan synthesis and myogenesis: a requirement for hyaluronan synthesis during myogenic differentiation independent of pericellular matrix formation. J. Biol. Chem. 2013, 288:13006-13021.
114. Goncharova V., Serobyan N., Iizuka S., Schraufstatter I., de Ridder A., Povaliy T., Wacker V., Itano N., Kimata K., Orlovskaja I.A., Yamaguchi Y., Khaldoyanidi S. Hyaluronan expressed by the hematopoietic microenvironment is required for bone marrow hematopoiesis. J. Biol. Chem. 2012, 287:25419-25433.
115. Riehl T.E., Ee X., Stenson W.F. Hyaluronic acid regulates normal intestinal and colonic growth in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G377-388.
116. Bourguignon L.Y., Zhu H., Zhou B., Diedrich F., Singleton P.A., Hung M.C. Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth. J. Biol. Chem. 2001, 276:48679-48692.
117. Meran S., Thomas D.W., Stephens P., Enoch S., Martin J., Steadman R., Phillips A.O. Hyaluronan facilitates transforming growth factor-beta1-mediated fibroblast proliferation. J. Biol. Chem. 2008, 283:6530-6545.
118. Kozlova I., Ruusala A., Voytyuk O., Skandalis S.S., Heldin P. IQGAP1 regulates hyaluronan-mediated fibroblast motility and proliferation. Cell. Signal. 2012, 24:1856-1862.
119. Gao F., Liu Y., He Y., Yang C., Wang Y., Shi X., Wei G. Hyaluronan oligosaccharides promote excisional wound healing through enhanced angiogenesis. Matrix Biol. 2010, 29:107-116.
120. Jenkins R.H., Thomas G.J., Williams J.D., Steadman R. Myofibroblastic differentiation leads to hyaluronan accumulation through reduced hyaluronan turnover. J. Biol. Chem. 2004, 279:41453-41460.
121. Webber J., Jenkins R.H., Meran S., Phillips A., Steadman R. Modulation of TGFbeta1-dependent myofibroblast differentiation by hyaluronan. Am. J. Pathol. 2009, 175:148-160.
122. Takahashi Y., Li L., Kamiryo M., Asteriou T., Moustakas A., Yamashita H., Heldin P. Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1/GRO1-dependent manner. J. Biol. Chem. 2005, 280:24195-24204.
123. Kavalkovich K.W., Boynton R.E., Murphy J.M., Barry F. Chondrogenic differentiation of human mesenchymal stem cells within an alginate layer culture system. In Vitro Cell. Dev. Biol. Anim. 2002, 38:457-466.
124. Tsukahara S., Ikeda R., Goto S., Yoshida K., Mitsumori R., Sakamoto Y., Tajima A., Yokoyama T., Toh S., Furukawa K., Inoue I. Tumour necrosis factor alpha-stimulated gene-6 inhibits osteoblastic differentiation of human mesenchymal stem cells induced by osteogenic differentiation medium and BMP-2. Biochem. J. 2006, 398:595-603.
125. Iocono J.A., Bisignani G.J., Krummel T.M., Ehrlich H.P. Inhibiting the differentiation of myocardiocytes by hyaluronic acid. J. Surg. Res. 1998, 76:111-116.
126. Ariel A., Lider O., Brill A., Cahalon L., Savion N., Varon D., Hershkoviz R. Induction of interactions between CD44 and hyaluronic acid by a short exposure of human T cells to diverse pro-inflammatory mediators. Immunology 2000, 100:345-351.
127. Baaten B.J., Li C.R., Deiro M.F., Lin M.M., Linton P.J., Bradley L.M. CD44 regulates survival and memory development in Th1 cells. Immunity 2010, 32:104-115.
128. Rafi A., Nagarkatti M., Nagarkatti P.S. Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood 1997, 89:2901-2908.
129. Firan M., Dhillon S., Estess P., Siegelman M.H. Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44. Blood 2006, 107:619-627.
130. Wu C., Thalhamer T., Franca R.F., Xiao S., Wang C., Hotta C., Zhu C., Hirashima M., Anderson A.C., Kuchroo V.K. Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 2014, 41:270-282.
131. Khan A.I., Kerfoot S.M., Heit B., Liu L., Andonegui G., Ruffell B., Johnson P., Kubes P. Role of CD44 and hyaluronan in neutrophil recruitment. J. Immunol. 2004, 173:7594-7601.
132. Rouschop K.M., Roelofs J.J., Claessen N., da Costa Martins P., Zwaginga J.J., Pals S.T., Weening J.J., Florquin S. Protection against renal ischemia reperfusion injury by CD44 disruption. J. Am. Soc. Nephrol. 2005, 16:2034-2043.
133. Yamasaki K., Muto J., Taylor K.R., Cogen A.L., Audish D., Bertin J., Grant E.P., Coyle A.J., Misaghi A., Hoffman H.M., Gallo R.L. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J. Biol. Chem. 2009, 284:12762-12771.
134. Stoop R., Gal I., Glant T.T., McNeish J.D., Mikecz K. Trafficking of CD44-deficient murine lymphocytes under normal and inflammatory conditions. Eur. J. Immunol. 2002, 32:2532-2542.
135. Suwan K., Choocheep K., Hatano S., Kongtawelert P., Kimata K., Watanabe H. Versican/PG-M assembles hyaluronan into extracellular matrix and inhibits CD44-mediated signaling toward premature senescence in embryonic fibroblasts. J. Biol. Chem. 2009, 284:8596-8604.
136. Lompardia S.L., Papademetrio D.L., Mascaro M., Alvarez E.M., Hajos S.E. Human leukemic cell lines synthesize hyaluronan to avoid senescence and resist chemotherapy. Glycobiology 2013, 23:1463-1476.
137. Rock K., Tigges J., Sass S., Schutze A., Florea A.M., Fender A.C., Theis F.J., Krutmann J., Boege F., Fritsche E., Reifenberger G., Fischer J.W. miR-23a-3p causes cellular senescence by targeting hyaluronan synthase 2: possible implication for skin aging. J Invest Dermatol 2015, 135:369-377.
138. Jung E.M., Kwon O., Kwon K.S., Cho Y.S., Rhee S.K., Min J.K., Oh D.B. Evidences for correlation between the reduced VCAM-1 expression and hyaluronan synthesis during cellular senescence of human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2011, 404:463-469.
139. Cirillo N., Vicidomini A., McCullough M., Gambardella A., Hassona Y., Prime S.S., Colella G. A hyaluronic acid-based compound inhibits fibroblast senescence induced by oxidative stress in vitro and prevents oral mucositis in vivo. J. Cell. Physiol. 2015, 230:1421-1429.
140. Pauloin T., Dutot M., Joly F., Warnet J.M., Rat P. High molecular weight hyaluronan decreases UVB-induced apoptosis and inflammation in human epithelial corneal cells. Mol. Vis. 2009, 15:577-583.
141. Ruffell B., Johnson P. Hyaluronan induces cell death in activated T cells through CD44. J. Immunol. 2008, 181:7044-7054.
142. Leu S.W., Shi L., Xu C., Zhao Y., Liu B., Li Y., Shiedlin A., Xiang C., Shen H., Quinn D.A., Hales C.A., Zhao H. TLR4 through IFN-beta promotes low molecular mass hyaluronan-induced neutrophil apoptosis. J. Immunol. 2011, 186:556-562.
143. Huang P.M., Syrkina O., Yu L., Dedaj R., Zhao H., Shiedlin A., Liu Y.Y., Garg H., Quinn D.A., Hales C.A. High MW hyaluronan inhibits smoke inhalation-induced lung injury and improves survival. Respirology 2010, 15:1131-1139.
144. Takazoe K., Tesch G.H., Hill P.A., Hurst L.A., Jun Z., Lan H.Y., Atkins R.C., Nikolic-Paterson D.J. CD44-mediated neutrophil apoptosis in the rat. Kidney Int. 2000, 58:1920-1930.
145. Wang Q., Teder P., Judd N.P., Noble P.W., Doerschuk C.M. CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am. J. Pathol. 2002, 161:2219-2228.
146. Wisniewski H.G., Hua J.C., Poppers D.M., Naime D., Vilcek J., Cronstein B.N. TNF/IL-1-inducible protein TSG-6 potentiates plasmin inhibition by inter-alpha-inhibitor and exerts a strong anti-inflammatory effect in vivo. J. Immunol. 1996, 156:1609-1615.
147. Tolg C., Telmer P., Turley E. Specific sizes of hyaluronan oligosaccharides stimulate fibroblast migration and excisional wound repair. PLoS One 2014, 9:e88479.
148. Svee K., White J., Vaillant P., Jessurun J., Roongta U., Krumwiede M., Johnson D., Henke C. Acute lung injury fibroblast migration and invasion of a fibrin matrix is mediated by CD44. J. Clin. Invest. 1996, 98:1713-1727.
149. Evanko S.P., Potter-Perigo S., Petty L.J., Workman G.A., Wight T.N. Hyaluronan controls the deposition of fibronectin and collagen and modulates TGF-beta1 induction of lung myofibroblasts. Matrix Biol. 2015, 42:74-92.
150. Evanko S.P., Angello J.C., Wight T.N. Formation of hyaluronan- and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1004-1013.
151. Savani R.C., Wang C., Yang B., Zhang S., Kinsella M.G., Wight T.N., Stern R., Nance D.M., Turley E.A. Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM. J. Clin. Invest. 1995, 95:1158-1168.
152. Herrera M.B., Bussolati B., Bruno S., Morando L., Mauriello-Romanazzi G., Sanavio F., Stamenkovic I., Biancone L., Camussi G. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007, 72:430-441.
153. Legg J.W., Lewis C.A., Parsons M., Ng T., Isacke C.M. A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat. Cell Biol. 2002, 4:399-407.
154. Acharya P.S., Majumdar S., Jacob M., Hayden J., Mrass P., Weninger W., Assoian R.K., Pure E. Fibroblast migration is mediated by CD44-dependent TGF beta activation. J. Cell Sci. 2008, 121:1393-1402.
155. Henke C.A., Roongta U., Mickelson D.J., Knutson J.R., McCarthy J.B. CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J. Clin. Invest. 1996, 97:2541-2552.
156. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
157. Allison P., Espiritu D., Barnett J.V., Camenisch T.D. Type III TGFbeta receptor and Src direct hyaluronan-mediated invasive cell motility. Cell. Signal. 2015, 27:453-459.
158. Veiseh M., Kwon D.H., Borowsky A.D., Tolg C., Leong H.S., Lewis J.D., Turley E.A., Bissell M.J. Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E1731-1739.
159. Li Y., Jiang D., Liang J., Meltzer E.B., Gray A., Miura R., Wogensen L., Yamaguchi Y., Noble P.W. Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J. Exp. Med. 2011, 208:1459-1471.
160. Nairn A.V., Kinoshita-Toyoda A., Toyoda H., Xie J., Harris K., Dalton S., Kulik M., Pierce J.M., Toida T., Moremen K.W., Linhardt R.J. Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J. Proteome Res. 2007, 6:4374-4387.
161. Schraufstatter I.U., Serobyan N., Loring J., Khaldoyanidi S.K. Hyaluronan is required for generation of hematopoietic cells during differentiation of human embryonic stem cells. J. Stem. Cells 2010, 5:9-21.
162. Choudhary M., Zhang X., Stojkovic P., Hyslop L., Anyfantis G., Herbert M., Murdoch A.P., Stojkovic M., Lako M. Putative role of hyaluronan and its related genes, HAS2 and RHAMM, in human early preimplantation embryogenesis and embryonic stem cell characterization. Stem Cells 2007, 25:3045-3057.
163. Choi H.R., Kang Y.A., Na J.I., Huh S.Y., Huh C.H., Kim K.H., Park K.C. Oligosaccharides of hyaluronic acid increased epidermal cell stemness by modulation of integrin expression. J. Cosmet. Dermatol. 2012, 11:290-296.
164. Calloni R., Cordero E.A., Henriques J.A., Bonatto D. Reviewing and updating the major molecular markers for stem cells. Stem Cells Dev. 2013, 22:1455-1476.
165. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
166. Zoller M. CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells. Front. Immunol. 2015, 6:235.
167. Matrosova V.Y., Orlovskaya I.A., Serobyan N., Khaldoyanidi S.K. Hyaluronic acid facilitates the recovery of hematopoiesis following 5-fluorouracil administration. Stem Cells 2004, 22:544-555.
168. Deed R., Rooney P., Kumar P., Norton J.D., Smith J., Freemont A.J., Kumar S. Early-response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non-angiogenic, high-molecular-weight hyaluronan. Int. J. Cancer 1997, 71:251-256.
169. Cao G., Savani R.C., Fehrenbach M., Lyons C., Zhang L., Coukos G., Delisser H.M. Involvement of endothelial CD44 during in vivo angiogenesis. Am. J. Pathol. 2006, 169:325-336.
170. Noble P.W. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin. Chest Med. 2006, 27:S11-16. v.
171. Bjermer L., Lundgren R., Hallgren R. Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax 1989, 44:126-131.
172. Westergren-Thorsson G., Sime P., Jordana M., Gauldie J., Sarnstrand B., Malmstrom A. Lung fibroblast clones from normal and fibrotic subjects differ in hyaluronan and decorin production and rate of proliferation. Int. J. Biochem. Cell Biol. 2004, 36:1573-1584.
173. Webber J., Meran S., Steadman R., Phillips A. Hyaluronan orchestrates transforming growth factor-beta1-dependent maintenance of myofibroblast phenotype. J. Biol. Chem. 2009, 284:9083-9092.
174. Simpson R.M., Meran S., Thomas D., Stephens P., Bowen T., Steadman R., Phillips A. Age-related changes in pericellular hyaluronan organization leads to impaired dermal fibroblast to myofibroblast differentiation. Am. J. Pathol. 2009, 175:1915-1928.
175. Nettelbladt O., Tengblad A., Hallgren R. High-dose corticosteroids during bleomycin-induced alveolitis in the rat do not suppress the accumulation of hyaluronan (hyaluronic acid) in lung tissue. Eur. Respir. J. 1990, 3:421-428.
176. Teder P., Heldin P. Mechanism of impaired local hyaluronan turnover in bleomycin-induced lung injury in rat. Am. J. Respir. Cell Mol. Biol. 1997, 17:376-385.
177. da Silva Bitencourt C., Gelfuso G.M., Pereira P.A., de Assis P.A., Tefe-Silva C., Ramos S.G., Arantes E.C., Faccioli L.H. Hyaluronidase-loaded PLGA microparticles as a new strategy for the treatment of pulmonary fibrosis. Tissue Eng. A 2015, 21:246-256.
178. Skurikhin E.G., Pershina O.V., Reztsova A.M., Ermakova N.N., Khmelevskaya E.S., Krupin V.A., Stepanova I.E., Artamonov A.V., Bekarev A.A., Madonov P.G., Dygai A.M. Modulation of bleomycin-induced lung fibrosis by pegylated hyaluronidase and dopamine receptor antagonist in mice. PLoS One 2015, 10:e0125065.
179. Yatagai Y., Sakamoto T., Yamada H., Masuko H., Kaneko Y., Iijima H., Naito T., Noguchi E., Hirota T., Tamari M., Konno S., Nishimura M., Hizawa N. Genomewide association study identifies HAS2 as a novel susceptibility gene for adult asthma in a Japanese population. Clin. Exp. Allergy 2014, 44:1327-1334.
180. Sahu S., Lynn W.S. Hyaluronic acid in the pulmonary secretions of patients with asthma. Biochem. J. 1978, 173:565-568.
181. Bousquet J., Chanez P., Lacoste J.Y., Enander I., Venge P., Peterson C., Ahlstedt S., Michel F.B., Godard P. Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma. J. Allergy Clin. Immunol. 1991, 88:649-660.
182. Ghosh S., Hoselton S.A., Wanjara S.B., Carlson J., McCarthy J.B., Dorsam G.P., Schuh J.M. Hyaluronan stimulates ex vivo B lymphocyte chemotaxis and cytokine production in a murine model of fungal allergic asthma. Immunobiology 2015, 220:899-909.
183. Liang J., Jiang D., Jung Y., Xie T., Ingram J., Church T., Degan S., Leonard M., Kraft M., Noble P.W. Role of hyaluronan and hyaluronan-binding proteins in human asthma. J. Allergy Clin. Immunol. 2011, 128:403-411. e403.
184. Ohkawara Y., Tamura G., Iwasaki T., Tanaka A., Kikuchi T., Shirato K. Activation and transforming growth factor-beta production in eosinophils by hyaluronan. Am. J. Respir. Cell Mol. Biol. 2000, 23:444-451.
185. Zhu Z., Lee C.G., Zheng T., Chupp G., Wang J., Homer R.J., Noble P.W., Hamid Q., Elias J.A. Airway inflammation and remodeling in asthma. Lessons from interleukin 11 and interleukin 13 transgenic mice. Am. J. Respir. Crit. Care Med. 2001, 164:S67-70.
186. Reeves S.R., Kolstad T., Lien T.Y., Elliott M., Ziegler S.F., Wight T.N., Debley J.S. Asthmatic airway epithelial cells differentially regulate fibroblast expression of extracellular matrix components. J. Allergy Clin. Immunol. 2014, 134:663-670. e661.
187. Dentener M.A., Vernooy J.H., Hendriks S., Wouters E.F. Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung function and local inflammation. Thorax 2005, 60:114-119.
188. Kalay N., Elcik D., Canatan H., Kaya M.G., Yarlioglues M., Oguzhan A., Dweik R.A., Aytekin M. Elevated plasma hyaluronan levels in pulmonary hypertension. Tohoku J. Exp. Med. 2013, 230:7-11.
189. Karmouty-Quintana H., Weng T., Garcia-Morales L.J., Chen N.Y., Pedroza M., Zhong H., Molina J.G., Bunge R., Bruckner B.A., Xia Y., Johnston R.A., Loebe M., Zeng D., Seethamraju H., Belardinelli L., Blackburn M.R. Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2013, 49:1038-1047.
190. Klagas I., Goulet S., Karakiulakis G., Zhong J., Baraket M., Black J.L., Papakonstantinou E., Roth M. Decreased hyaluronan in airway smooth muscle cells from patients with asthma and COPD. Eur. Respir. J. 2009, 34:616-628.
191. Cantor J., Armand G., Turino G. Lung hyaluronan levels are decreased in alpha-1 antiprotease deficiency COPD. Respir. Med. 2015, 109:656-659.
192. Bracke K.R., Dentener M.A., Papakonstantinou E., Vernooy J.H., Demoor T., Pauwels N.S., Cleutjens J., van Suylen R., Joos G.F., Brusselle G.G., Wouters E.F. Enhanced deposition of low weight hyaluronan in lungs of cigarette smoke-exposed mice. Am. J. Respir. Cell Mol. Biol. 2009, 42:753-761.
193. Eurlings I.M., Dentener M.A., Mercken E.M., de Cabo R., Bracke K.R., Vernooy J.H., Wouters E.F., Reynaert N.L. A comparative study of matrix remodeling in chronic models for COPD; mechanistic insights into the role of TNF-alpha. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 307:L557-565.
194. Tazaki G., Kondo T., Tajiri S., Tsuji C., Shioya S., Tanigaki T. Functional residual capacity and airway resistance in rats of COPD model induced by systemic hyaluronidase. Tokai J. Exp. Clin. Med. 2006, 31:125-127.
195. Cantor J., Shteyngart B. Does lysozyme play a role in the pathogenesis of COPD?. Med. Hypotheses 2015, 84:551-554.
196. Cantor J.O., Cerreta J.M., Ochoa M., Ma S., Chow T., Grunig G., Turino G.M. Aerosolized hyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema. Exp. Lung Res. 2005, 31:417-430.
197. Cantor J.O., Cerreta J.M., Ochoa M., Ma S., Liu M., Turino G.M. Therapeutic effects of hyaluronan on smoke-induced elastic fiber injury: does delayed treatment affect efficacy?. Lung 2011, 189:51-56.
198. Cantor J.O. Potential therapeutic applications of hyaluronan in the lung. Int. J. Chron. Obstruct. Pulmon. Dis. 2007, 2:283-288.
199. Riise G.C., Schersten H., Nilsson F., Ryd W., Andersson B.A. Activation of eosinophils and fibroblasts assessed by eosinophil cationic protein and hyaluronan in BAL. Association with acute rejection in lung transplant recipients. Chest 1996, 110:89-96.
200. Todd J.L., Wang X., Sugimoto S., Kennedy V.E., Zhang H.L., Pavlisko E.N., Kelly F.L., Huang H., Kreisel D., Palmer S.M., Gelman A.E. Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. Am. J. Respir. Crit. Care Med. 2014, 189:556-566.
201. Johnsson C., Tufveson G. Serum hyaluronan-a potential marker of cardiac allograft rejection?. J. Heart Lung Transplant. 2006, 25:544-549.
202. Zhang W., Gao L., Qi S., Liu D., Xu D., Peng J., Daloze P., Chen H., Buelow R. Blocking of CD44-hyaluronic acid interaction prolongs rat allograft survival. Transplantation 2000, 69:665-667.
203. Knoflach A., Magee C., Denton M.D., Kim K.S., Buelow R., Hancock W.W., Sayegh M.H. Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection. Transplantation 1999, 67:909-914.
204. Johnsson C., Hallgren R., Elvin A., Gerdin B., Tufveson G. Hyaluronidase ameliorates rejection-induced edema. Transpl. Int. 1999, 12:235-243.
205. Inokoshi Y., Tanino Y., Wang X., Sato S., Fukuhara N., Nikaido T., Fukuhara A., Saito J., Frevert C.W., Munakata M. Clinical significance of serum hyaluronan in chronic fibrotic interstitial pneumonia. Respirology 2013, 18:1236-1243.
206. van der Windt G.J., Florquin S., de Vos A.F., van't Veer C., Queiroz K.C., Liang J., Jiang D., Noble P.W., van der Poll T. CD44 deficiency is associated with increased bacterial clearance but enhanced lung inflammation during Gram-negative pneumonia. Am. J. Pathol. 2010, 177:2483-2494.
207. Collins S.L., Black K.E., Chan-Li Y., Ahn Y.H., Cole P.A., Powell J.D., Horton M.R. Hyaluronan fragments promote inflammation by down-regulating the anti-inflammatory A2a receptor. Am. J. Respir. Cell Mol. Biol. 2011, 45:675-683.
208. Guechot J., Poupon R.E., Giral P., Balkau B., Giboudeau J., Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J. Hepatol. 1994, 20:388-393.
209. Neuman M.G., Cohen L.B., Nanau R. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin. Biochem. 2015, [Epub ahead of print]. 10.1016/j.clinbiochem.2015.07.019.
210. Lichtinghagen R., Pietsch D., Bantel H., Manns M.P., Brand K., Bahr M.J. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J. Hepatol. 2013, 59:236-242.
211. Rostami S., Parsian H. Hyaluronic acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis. Hepat. Mon. 2013, 13:e13787.
212. Arain S.A., Meo S.A., Jamal Q. Serum hyaluronic acid level does not reliably differentiate minimal and significant liver disease in chronic hepatitis C. Saudi Med. J. 2011, 32:1241-1245.
213. Wolf D., Schumann J., Koerber K., Kiemer A.K., Vollmar A.M., Sass G., Papadopoulos T., Bang R., Klein S.D., Brune B., Tiegs G. Low-molecular-weight hyaluronic acid induces nuclear factor-kappaB-dependent resistance against tumor necrosis factor alpha-mediated liver injury in mice. Hepatology 2001, 34:535-547.
214. Kimura K., Nagaki M., Kakimi K., Saio M., Saeki T., Okuda Y., Kuwata K., Moriwaki H. Critical role of CD44 in hepatotoxin-mediated liver injury. J. Hepatol. 2008, 48:952-961.
215. Papakonstantinou E., Roth M., Block L.H., Mirtsou-Fidani V., Argiriadis P., Karakiulakis G. The differential distribution of hyaluronic acid in the layers of human atheromatic aortas is associated with vascular smooth muscle cell proliferation and migration. Atherosclerosis 1998, 138:79-89.
216. Fischer J.W., Schror K. Regulation of hyaluronan synthesis by vasodilatory prostaglandins. Thromb. Haemost. 2007, 98:287-295.
217. Chai S., Chai Q., Danielsen C.C., Hjorth P., Nyengaard J.R., Ledet T., Yamaguchi Y., Rasmussen L.M., Wogensen L. Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ. Res. 2005, 96:583-591.
218. Nagy N., Freudenberger T., Melchior-Becker A., Rock K., Ter Braak M., Jastrow H., Kinzig M., Lucke S., Suvorava T., Kojda G., Weber A.A., Sorgel F., Levkau B., Ergun S., Fischer J.W. Inhibition of hyaluronan synthesis accelerates murine atherosclerosis: novel insights into the role of hyaluronan synthesis. Circulation 2010, 122:2313-2322.
219. Cuff C.A., Kothapalli D., Azonobi I., Chun S., Zhang Y., Belkin R., Yeh C., Secreto A., Assoian R.K., Rader D.J., Pure E. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J. Clin. Invest. 2001, 108:1031-1040.
220. Zhao L., Lee E., Zukas A.M., Middleton M.K., Kinder M., Acharya P.S., Hall J.A., Rader D.J., Pure E. CD44 expressed on both bone marrow-derived and non-bone marrow-derived cells promotes atherogenesis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1283-1289.
221. Mine S., Okada Y., Kawahara C., Tabata T., Tanaka Y. Serum hyaluronan concentration as a marker of angiopathy in patients with diabetes mellitus. Endocr. J. 2006, 53:761-766.
222. Mahadevan P., Larkins R.G., Fraser J.R., Fosang A.J., Dunlop M.E. Increased hyaluronan production in the glomeruli from diabetic rats: a link between glucose-induced prostaglandin production and reduced sulphated proteoglycan. Diabetologia 1995, 38:298-305.
223. Bertheim U., Engstrom-Laurent A., Hofer P.A., Hallgren P., Asplund J., Hellstrom S. Loss of hyaluronan in the basement membrane zone of the skin correlates to the degree of stiff hands in diabetic patients. Acta Derm. Venereol. 2002, 82:329-334.
224. Cechowska-Pasko M., Palka J., Bankowski E. Decreased biosynthesis of glycosaminoglycans in the skin of rats with chronic diabetes mellitus. Exp. Toxicol. Pathol. 1999, 51:239-243.
225. Mahadevan P., Larkins R.G., Fraser J.R., Dunlop M.E. Effect of prostaglandin E2 and hyaluronan on mesangial cell proliferation. A potential contribution to glomerular hypercellularity in diabetes. Diabetes 1996, 45:44-50.
226. Marutsuka K., Woodcock-Mitchell J., Sakamoto T., Sobel B.E., Fujii S. Pathogenetic implications of hyaluronan-induced modification of vascular smooth muscle cell fibrinolysis in diabetes. Coron. Artery Dis. 1998, 9:177-184.
227. Kodama K., Horikoshi M., Toda K., Yamada S., Hara K., Irie J., Sirota M., Morgan A.A., Chen R., Ohtsu H., Maeda S., Kadowaki T., Butte A.J. Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7049-7054.
228. Weiss L., Slavin S., Reich S., Cohen P., Shuster S., Stern R., Kaganovsky E., Okon E., Rubinstein A.M., Naor D. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:285-290.
229. Soulie P., Chassot A., Ernandez T., Montesano R., Feraille E. Spatially restricted hyaluronan production by Has2 drives epithelial tubulogenesis in vitro. Am. J. Physiol. Cell Physiol. 2014, 307:C745-759.
230. Nishikawa K., Andres G., Bhan A.K., McCluskey R.T., Collins A.B., Stow J.L., Stamenkovic I. Hyaluronate is a component of crescents in rat autoimmune glomerulonephritis. Lab. Invest. 1993, 68:146-153.
231. Yung S., Tsang R.C., Leung J.K., Chan T.M. Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta. Kidney Int. 2006, 69:272-280.
232. Kubo M., Kikuchi K., Yazawa N., Fujimoto M., Tamaki T., Tamaki K. Increased serum concentration of hyaluronate in dermatomyositis patients. Arch. Dermatol. Res. 1998, 290:579-581.
233. Hallgren R., Engstrom-Laurent A., Nisbeth U. Circulating hyaluronate. A potential marker of altered metabolism of the connective tissue in uremia. Nephron 1987, 46:150-154.
234. Turney J.H., Davison A.M., Forbes M.A., Cooper E.H. Hyaluronic acid in end-stage renal failure treated by haemodialysis: clinical correlates and implications. Nephrol. Dial. Transplant. 1991, 6:566-570.
235. Stenvinkel P., Heimburger O., Wang T., Lindholm B., Bergstrom J., Elinder C.G. High serum hyaluronan indicates poor survival in renal replacement therapy. Am. J. Kidney Dis. 1999, 34:1083-1088.
236. Edward M., Fitzgerald L., Thind C., Leman J., Burden A.D. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. Br. J. Dermatol. 2007, 156:473-479.
237. Jun Z., Hill P.A., Lan H.Y., Foti R., Mu W., Atkins R.C., Nikolic-Paterson D.J. CD44 and hyaluronan expression in the development of experimental crescentic glomerulonephritis. Clin. Exp. Immunol. 1997, 108:69-77.
238. Matsuda M., Shikata K., Shimizu F., Suzuki Y., Miyasaka M., Kawachi H., Kawashima H., Wada J., Sugimoto H., Shikata Y., Ogawa D., Tojo S.J., Akima K., Makino H. Therapeutic effect of sulphated hyaluronic acid, a potential selectin-blocking agent, on experimental progressive mesangial proliferative glomerulonephritis. J. Pathol. 2002, 198:407-414.
239. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
240. de la Motte C.A., Kessler S.P. The role of hyaluronan in innate defense responses of the intestine. Int. J. Cell Biol. 2015, 2015:481301.
241. Kessler S., Rho H., West G., Fiocchi C., Drazba J., de la Motte C. Hyaluronan (HA) deposition precedes and promotes leukocyte recruitment in intestinal inflammation. Clin. Transl. Sci. 2008, 1:57-61.
242. de La Motte C.A., Hascall V.C., Calabro A., Yen-Lieberman B., Strong S.A. Mononuclear leukocytes preferentially bind via CD44 to hyaluronan on human intestinal mucosal smooth muscle cells after virus infection or treatment with poly(I.C). J. Biol. Chem. 1999, 274:30747-30755.
243. Bandyopadhyay S.K., de la Motte C.A., Kessler S.P., Hascall V.C., Hill D.R., Strong S.A. Hyaluronan-mediated leukocyte adhesion and dextran sulfate sodium-induced colitis are attenuated in the absence of signal transducer and activator of transcription 1. Am. J. Pathol. 2008, 173:1361-1368.
244. Kessler S.P., Obery D.R., de la Motte C. Hyaluronan synthase 3 null mice exhibit decreased intestinal inflammation and tissue damage in the DSS-induced colitis model. Int. J. Cell Biol. 2015, 2015:745237.
245. Collins C.B., Ho J., Wilson T.E., Wermers J.D., Tlaxca J.L., Lawrence M.B., Solga M., Lannigan J., Rivera-Nieves J. CD44 deficiency attenuates chronic murine ileitis. Gastroenterology 2008, 135:1993-2002.
246. Albeiroti S., Ayasoufi K., Hill D.R., Shen B., de la Motte C.A. Platelet hyaluronidase-2: an enzyme that translocates to the surface upon activation to function in extracellular matrix degradation. Blood 2015, 125:1460-1469.
247. Zheng L., Riehl T.E., Stenson W.F. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology 2009, 137:2041-2051.
248. Riehl T.E., Foster L., Stenson W.F. Hyaluronic acid is radioprotective in the intestine through a TLR4 and COX-2-mediated mechanism. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G309-316.
249. McAtee C.O., Barycki J.J., Simpson M.A. Emerging roles for hyaluronidase in cancer metastasis and therapy. Adv. Cancer Res. 2014, 123:1-34.
250. Tian X., Azpurua J., Hine C., Vaidya A., Myakishev-Rempel M., Ablaeva J., Mao Z., Nevo E., Gorbunova V., Seluanov A. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 2013, 499:346-349.
251. Weber G.F., Bronson R.T., Ilagan J., Cantor H., Schmits R., Mak T.W. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res. 2002, 62:2281-2286.
252. Godar S., Ince T.A., Bell G.W., Feldser D., Donaher J.L., Bergh J., Liu A., Miu K., Watnick R.S., Reinhardt F., McAllister S.S., Jacks T., Weinberg R.A. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008, 134:62-73.
253. Zhang S., Wu C.C., Fecteau J.F., Cui B., Chen L., Zhang L., Wu R., Rassenti L., Lao F., Weigand S., Kipps T.J. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:6127-6132.
254. Cresta F., Naselli A., Favilli F., Casciaro R. Inhaled hypertonic saline + hyaluronic acid in cystic fibrosis with asthma-like symptoms: a new therapeutic chance, BMJ Case Rep, 2013 2013.
255. Ros M., Casciaro R., Lucca F., Troiani P., Salonini E., Favilli F., Quattrucci S., Sher D., Assael B.M. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. J. Aerosol Med. Pulm. Drug Deliv. 2014, 27:133-137.
256. Engelhardt P.F., Morakis N., Daha L.K., Esterbauer B., Riedl C.R. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int. Urogynecol. J. 2011, 22:401-405.
257. Liu Y.Y., Lee C.H., Dedaj R., Zhao H., Mrabat H., Sheidlin A., Syrkina O., Huang P.M., Garg H.G., Hales C.A., Quinn D.A. High-molecular-weight hyaluronan-a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats. Crit. Care 2008, 12:R102.
258. Toole B.P., Ghatak S., Misra S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr. Pharm. Biotechnol. 2008, 9:249-252.
259. Ogawa D., Shikata K., Matsuda M., Akima K., Iwahashi M., Okada S., Tsuchiyama Y., Shikata Y., Wada J., Makino H. Sulfated hyaluronic acid, a potential selectin inhibitor, ameliorates experimentally induced crescentic glomerulonephritis. Nephron Exp. Nephrol. 2005, 99:e26-32.
260. Hintze V., Moeller S., Schnabelrauch M., Bierbaum S., Viola M., Worch H., Scharnweber D. Modifications of hyaluronan influence the interaction with human bone morphogenetic protein-4 (hBMP-4). Biomacromolecules 2009, 10:3290-3297.
261. Hintze V., Miron A., Moeller S., Schnabelrauch M., Wiesmann H.P., Worch H., Scharnweber D. Sulfated hyaluronan and chondroitin sulfate derivatives interact differently with human transforming growth factor-beta1 (TGF-beta1). Acta Biomater. 2012, 8:2144-2152.
262. Liao Y.H., Jones S.A., Forbes B., Martin G.P., Brown M.B. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Deliv. 2005, 12:327-342.
263. Cai S., Alhowyan A.A., Yang Q., Forrest W.C., Shnayder Y., Forrest M.L. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates. J. Drug Target. 2014, 22:648-657.
264. Montagner I.M., Merlo A., Carpanese D., Zuccolotto G., Renier D., Campisi M., Pasut G., Zanovello P., Rosato A. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience 2015, 2:373-381.
265. Montagner I.M., Merlo A., Zuccolotto G., Renier D., Campisi M., Pasut G., Zanovello P., Rosato A. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs. PLoS One 2014, 9:e112240.
266. Banzato A., Bobisse S., Rondina M., Renier D., Bettella F., Esposito G., Quintieri L., Melendez-Alafort L., Mazzi U., Zanovello P., Rosato A. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 2008, 14:3598-3606.
267. Cai S., Xie Y., Bagby T.R., Cohen M.S., Forrest M.L. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J. Surg. Res. 2008, 147:247-252.
268. Song S., Qi H., Xu J., Guo P., Chen F., Li F., Yang X., Sheng N., Wu Y., Pan W. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm. Res. 2014, 31:2988-3005.
269. Lu X., Huang X. Design and syntheses of hyaluronan oligosaccharide conjugates as inhibitors of CD44-hyaluronan binding. Glycoconj. J. 2015, 32:549-556.
270. El-Dakdouki M.H., Xia J., Zhu D.C., Kavunja H., Grieshaber J., O'Reilly S., McCormick J.J., Huang X. Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles. ACS Appl. Mater. Interfaces 2014, 6:697-705.
271. Gibbs P., Clingan P.R., Ganju V., Strickland A.H., Wong S.S., Tebbutt N.C., Underhill C.R., Fox R.M., Clavant S.P., Leung J., Pho M., Brown T.J. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother. Pharmacol. 2011, 67:153-163.
272. Yang J.A., Kong W.H., Sung D.K., Kim H., Kim T.H., Lee K.C., Hahn S.K. Hyaluronic acid-tumor necrosis factor-related apoptosis-inducing ligand conjugate for targeted treatment of liver fibrosis. Acta Biomater. 2015, 12:174-182.
273. Jederstrom G., Andersson A., Grasjo J., Sjoholm I. Formulating insulin for oral administration: preparation of hyaluronan-insulin complex. Pharm. Res. 2004, 21:2040-2047.
274. Jederstrom G., Grasjo, Nordin A., Sjoholm I., Andersson A. Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes. Diabetes Technol. Ther. 2005, 7:948-957.
275. Nakamura T., Takagaki K., Shibata S., Tanaka K., Higuchi T., Endo M. Hyaluronic-acid-deficient extracellular matrix induced by addition of 4-methylumbelliferone to the medium of cultured human skin fibroblasts. Biochem. Biophys. Res. Commun. 1995, 208:470-475.
276. Kultti A., Pasonen-Seppanen S., Jauhiainen M., Rilla K.J., Karna R., Pyoria E., Tammi R.H., Tammi M.I. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp. Cell Res. 2009, 315:1914-1923.
277. Nagy N., Kuipers H.F., Frymoyer A.R., Ishak H.D., Bollyky J.B., Wight T.N., Bollyky P.L. 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front. Immunol. 2015, 6:123.
278. Abate A., Dimartino V., Spina P., Costa P.L., Lombardo C., Santini A., Del Piano M., Alimonti P. Hymecromone in the treatment of motor disorders of the bile ducts: a multicenter, double-blind, placebo-controlled clinical study. Drugs Exp. Clin. Res. 2001, 27:223-231.
279. McKallip R.J., Hagele H.F., Uchakina O.N. Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation. Toxins (Basel) 2013, 5:1814-1826.
280. McKallip R.J., Ban H., Uchakina O.N. Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses LPS-induced lung inflammation. Inflammation 2015, 38:1250-1259.
281. Mueller A.M., Yoon B.H., Sadiq S.A. Inhibition of hyaluronan synthesis protects against central nervous system (CNS) autoimmunity and increases CXCL12 expression in the inflamed CNS. J. Biol. Chem. 2014, 289:22888-22899.
282. Colombaro V., Decleves A.E., Jadot I., Voisin V., Giordano L., Habsch I., Nonclercq D., Flamion B., Caron N. Inhibition of hyaluronan is protective against renal ischaemia-reperfusion injury. Nephrol. Dial. Transplant. 2013, 28:2484-2493.
283. Yoshioka Y., Kozawa E., Urakawa H., Arai E., Futamura N., Zhuo L., Kimata K., Ishiguro N., Nishida Y. Suppression of hyaluronan synthesis alleviates inflammatory responses in murine arthritis and in human rheumatoid synovial fibroblasts. Arthritis Rheum. 2013, 65:1160-1170.
284. Piccioni F., Fiore E., Bayo J., Atorrasagasti C., Peixoto E., Rizzo M., Malvicini M., Tirado-Gonzalez I., Garcia M.G., Alaniz L., Mazzolini G. 4-Methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis. Glycobiology 2015, 25:825-835.
285. Piccioni F., Malvicini M., Garcia M.G., Rodriguez A., Atorrasagasti C., Kippes N., Piedra Buena I.T., Rizzo M.M., Bayo J., Aquino J., Viola M., Passi A., Alaniz L., Mazzolini G. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology 2012, 22:400-410.
286. Adams L. Adjuvants to local anaesthesia in ophthalmic surgery. Br. J. Ophthalmol. 2011, 95:1345-1349.
287. Yasuda T., Ribeiro L.G., Maroko P.R. Effect of hyaluronidase on experimental cerebral infarct size and mortality. Lab. Invest. 1982, 46:400-404.
288. Maroko P.R., Davidson D.M., Libby P., Hagan A.D., Braunwald E. Effects of hyaluronidase administration on myocardial ischemic injury in acute infarction. A preliminary study in 24 patients. Ann. Intern. Med. 1975, 82:516-520.
289. Roberts R., Braunwald E., Muller J.E., Croft C., Gold H.K., Hartwell T.D., Jaffe A.S., Mullin S.M., Parker C., Passamani E.R., et al. Effect of hyaluronidase on mortality and morbidity in patients with early peaking of plasma creatine kinase MB and non-transmural ischaemia. Multicentre investigation for the limitation of infarct size (MILIS). Br. Heart J. 1988, 60:290-298.
290. Girish K.S., Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: a biological overview. Life Sci. 2007, 80:1921-1943.
291. Furuya T., Yamagata S., Shimoyama Y., Fujihara M., Morishima N., Ohtsuki K. Biochemical characterization of glycyrrhizin as an effective inhibitor for hyaluronidases from bovine testis. Biol. Pharm. Bull. 1997, 20:973-977.
292. Harunari E., Imada C., Igarashi Y., Fukuda T., Terahara T., Kobayashi T. Hyaluromycin, a new hyaluronidase inhibitor of polyketide origin from marine Streptomyces sp. Mar. Drugs 2014, 12:491-507.
293. Orlent H., Hansen B.E., Willems M., Brouwer J.T., Huber R., Kullak-Ublick G.A., Gerken G., Zeuzem S., Nevens F., Tielemans W.C., Zondervan P.E., Lagging M., Westin J., Schalm S.W. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J. Hepatol. 2006, 45:539-546.
294. Yanagawa Y., Ogura M., Fujimoto E., Shono S., Okuda E. Effects and cost of glycyrrhizin in the treatment of upper respiratory tract infections in members of the Japanese maritime self-defense force: preliminary report of a prospective, randomized, double-blind, controlled, parallel-group, alternate-day treatment assignment clinical trial. Curr. Ther. Res. Clin. Exp. 2004, 65:26-33.
295. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
296. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., Feig C., Nakagawa T., Caldwell M.E., Zecchini H.I., Lolkema M.P., Jiang P., Kultti A., Thompson C.B., Maneval D.C., Jodrell D.I., Frost G.I., Shepard H.M., Skepper J.N., Tuveson D.A. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
297. Mummert M.E., Mohamadzadeh M., Mummert D.I., Mizumoto N., Takashima A. Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J. Exp. Med. 2000, 192:769-779.
298. Martin S.F., Dudda J.C., Bachtanian E., Lembo A., Liller S., Durr C., Heimesaat M.M., Bereswill S., Fejer G., Vassileva R., Jakob T., Freudenberg N., Termeer C.C., Johner C., Galanos C., Freudenberg M.A. Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J. Exp. Med. 2008, 205:2151-2162.
299. Mummert M.E., Mummert D., Edelbaum D., Hui F., Matsue H., Takashima A. Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J. Immunol. 2002, 169:4322-4331.
300. Stober V.P., Szczesniak C., Childress Q., Heise R.L., Bortner C., Hollingsworth J.W., Neuringer I.P., Palmer S.M., Garantziotis S. Bronchial epithelial injury in the context of alloimmunity promotes lymphocytic bronchiolitis through hyaluronan expression. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 306:L1045-1055.
301. Mummert M.E., Mummert D.I., Ellinger L., Takashima A. Functional roles of hyaluronan in B16-F10 melanoma growth and experimental metastasis in mice. Mol. Cancer Ther. 2003, 2:295-300.
302. Guan H., Nagarkatti P.S., Nagarkatti M. Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. J. Immunol. 2007, 179:3715-3723.
303. Tolg C., Hamilton S.R., Zalinska E., McCulloch L., Amin R., Akentieva N., Winnik F., Savani R., Bagli D.J., Luyt L.G., Cowman M.K., McCarthy J.B., Turley E.A. A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds. Am. J. Pathol. 2012, 181:1250-1270.
304. Rizzardi A.E., Vogel R.I., Koopmeiners J.S., Forster C.L., Marston L.O., Rosener N.K., Akentieva N., Price M.A., Metzger G.J., Warlick C.A., Henriksen J.C., Turley E.A., McCarthy J.B., Schmechel S.C. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. Cancer 2014, 120:1800-1809.
305. Piotrowicz R.S., Damaj B.B., Hachicha M., Incardona F., Howell S.B., Finlayson M. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol. Cancer Ther. 2011, 10:2072-2082.
306. Ugarte-Berzal E., Bailon E., Amigo-Jimenez I., Albar J.P., Garcia-Marco J.A., Garcia-Pardo A. A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells. J. Biol. Chem. 2014, 289:15340-15349.
307. Finlayson M. Modulation of CD44 activity by A6-peptide. Front. Immunol. 2015, 6:135.
308. Charrad R.S., Gadhoum Z., Qi J., Glachant A., Allouche M., Jasmin C., Chomienne C., Smadja-Joffe F. Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood 2002, 99:290-299.
309. Song G., Liao X., Zhou L., Wu L., Feng Y., Han Z.C. HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leuk. Res. 2004, 28:1089-1096.
310. Guo Y., Ma J., Wang J., Che X., Narula J., Bigby M., Wu M., Sy M.S. Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res. 1994, 54:1561-1565.
311. Breyer R., Hussein S., Radu D.L., Putz K.M., Gunia S., Hecker H., Samii M., Walter G.F., Stan A.C. Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J. Neurosurg. 2000, 92:140-149.
312. Haynes B.F., Hale L.P., Patton K.L., Martin M.E., McCallum R.M. Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum. 1991, 34:1434-1443.
313. Mikecz K., Brennan F.R., Kim J.H., Glant T.T. Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat. Med. 1995, 1:558-563.
314. Henke C., Bitterman P., Roongta U., Ingbar D., Polunovsky V. Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease. Am. J. Pathol. 1996, 149:1639-1650.
315. Seiter S., Weber B., Tilgen W., Zoller M. Down-modulation of host reactivity by anti-CD44 in skin transplantation. Transplantation 1998, 66:778-791.
316. Wang F., Chen J., Shao W., Xie B., Wang Y., Lan T., Thorlacius H., Qi Z. Anti-CD44 monoclonal antibody inhibits heart transplant rejection mediated by alloantigen-primed CD4(+) memory T cells in nude mice. Immunol. Investig. 2010, 39:807-819.
317. Runnels H.A., Weber G.L., Min J., Kudlacz E.M., Zobel J.F., Donovan C.B., Thiede M.A., Zhang J., Alpert R.B., Salafia M.A., Milici A.J., Burdette D., Bell R.R., Beebe J.S., Xu X. PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases. Adv. Ther. 2010, 27:168-180.
318. Chen D., McKallip R.J., Zeytun A., Do Y., Lombard C., Robertson J.L., Mak T.W., Nagarkatti P.S., Nagarkatti M. CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J. Immunol. 2001, 166:5889-5897.
319. Stoop R., Kotani H., McNeish J.D., Otterness I.G., Mikecz K. Increased resistance to collagen-induced arthritis in CD44-deficient DBA/1 mice. Arthritis Rheum. 2001, 44:2922-2931.
320. Wang X., Xu L., Wang H., Zhan Y., Pure E., Feuerstein G.Z. CD44 deficiency in mice protects brain from cerebral ischemia injury. J. Neurochem. 2002, 83:1172-1179.
321. Tolg C., Hamilton S.R., Morningstar L., Zhang J., Zhang S., Esguerra K.V., Telmer P.G., Luyt L.G., Harrison R., McCarthy J.B., Turley E.A. RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J. Biol. Chem. 2010, 285:26461-26474.
322. Foley J.P., Lam D., Jiang H., Liao J., Cheong N., McDevitt T.M., Zaman A., Wright J.R., Savani R.C. Toll-like receptor 2 (TLR2), transforming growth factor-beta, hyaluronan (HA), and receptor for HA-mediated motility (RHAMM) are required for surfactant protein A-stimulated macrophage chemotaxis. J. Biol. Chem. 2012, 287:37406-37419.
323. Ma X., Pearce J.D., Wilson D.B., English W.P., Edwards M.S., Geary R.L. Loss of the hyaluronan receptor RHAMM prevents constrictive artery wall remodeling. J. Vasc. Surg. 2014, 59:804-813.
324. Kouvidi K., Berdiaki A., Nikitovic D., Katonis P., Afratis N., Hascall V.C., Karamanos N.K., Tzanakakis G.N. Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J. Biol. Chem. 2011, 286:38509-38520.
325. Yamamura H., Zhang M., Markwald R.R., Mjaatvedt C.H. A heart segmental defect in the anterior-posterior axis of a transgenic mutant mouse. Dev. Biol. 1997, 186:58-72.
326. Williams D.R., Presar A.R., Richmond A.T., Mjaatvedt C.H., Hoffman S., Capehart A.A. Limb chondrogenesis is compromised in the versican deficient hdf mouse. Biochem. Biophys. Res. Commun. 2005, 334:960-966.
327. Dours-Zimmermann M.T., Maurer K., Rauch U., Stoffel W., Fassler R., Zimmermann D.R. Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the CNS. J. Neurosci. 2009, 29:7731-7742.
328. Choocheep K., Hatano S., Takagi H., Watanabe H., Kimata K., Kongtawelert P., Watanabe H. Versican facilitates chondrocyte differentiation and regulates joint morphogenesis. J. Biol. Chem. 2010, 285:21114-21125.
329. Little C.B., Meeker C.T., Hembry R.M., Sims N.A., Lawlor K.E., Golub S.B., Last K., Fosang A.J. Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development. Mol. Cell. Biol. 2005, 25:3388-3399.
330. Little C.B., Meeker C.T., Golub S.B., Lawlor K.E., Farmer P.J., Smith S.M., Fosang A.J. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Invest. 2007, 117:1627-1636.
331. Schledzewski K., Geraud C., Arnold B., Wang S., Grone H.J., Kempf T., Wollert K.C., Straub B.K., Schirmacher P., Demory A., Schonhaber H., Gratchev A., Dietz L., Thierse H.J., Kzhyshkowska J., Goerdt S. Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. J. Clin. Invest. 2011, 121:703-714.
332. Huang S.S., Liu I.H., Smith T., Shah M.R., Johnson F.E., Huang J.S. CRSBP-1/LYVE-l-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels. FEBS Lett. 2006, 580:6259-6268.
333. Fulop C., Szanto S., Mukhopadhyay D., Bardos T., Kamath R.V., Rugg M.S., Day A.J., Salustri A., Hascall V.C., Glant T.T., Mikecz K. Impaired cumulus mucification and female sterility in tumor necrosis factor-induced protein-6 deficient mice. Development 2003, 130:2253-2261.
334. Mahoney D.J., Mikecz K., Ali T., Mabilleau G., Benayahu D., Plaas A., Milner C.M., Day A.J., Sabokbar A. TSG-6 regulates bone remodeling through inhibition of osteoblastogenesis and osteoclast activation. J. Biol. Chem. 2008, 283:25952-25962.
335. Swaidani S., Cheng G., Lauer M.E., Sharma M., Mikecz K., Hascall V.C., Aronica M.A. TSG-6 protein is crucial for the development of pulmonary hyaluronan deposition, eosinophilia, and airway hyperresponsiveness in a murine model of asthma. J. Biol. Chem. 2013, 288:412-422.